Novavax, Inc.
NVAX
$9.06
-$0.29-3.10%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 596.34M | 1.12B | 1.06B | 1.08B | 1.25B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 596.34M | 1.12B | 1.06B | 1.08B | 1.25B |
| Cost of Revenue | 432.38M | 409.86M | 452.90M | 482.73M | 541.91M |
| Gross Profit | 163.96M | 713.62M | 611.75M | 595.99M | 713.06M |
| SG&A Expenses | 126.76M | 150.38M | 194.93M | 229.61M | 290.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 559.14M | 560.24M | 647.83M | 712.33M | 832.15M |
| Operating Income | 37.20M | 563.24M | 416.82M | 366.39M | 422.81M |
| Income Before Tax | -86.19M | 442.17M | 350.68M | 431.39M | 488.52M |
| Income Tax Expenses | 1.65M | 1.87M | 8.94M | 8.56M | 9.82M |
| Earnings from Continuing Operations | -87.84 | 440.30 | 341.75 | 422.82 | 478.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -87.84M | 440.30M | 341.75M | 422.82M | 478.70M |
| EBIT | 37.20M | 563.24M | 416.82M | 366.39M | 422.81M |
| EBITDA | 59.53M | 590.85M | 451.83M | 407.51M | 467.50M |
| EPS Basic | -0.54 | 2.74 | 2.13 | 2.61 | 3.05 |
| Normalized Basic EPS | 0.24 | 2.27 | 1.69 | 1.52 | 1.79 |
| EPS Diluted | -0.58 | 2.41 | 1.79 | 2.28 | 2.66 |
| Normalized Diluted EPS | 0.20 | 2.05 | 1.47 | 1.30 | 1.53 |
| Average Basic Shares Outstanding | 650.18M | 647.95M | 645.66M | 643.36M | 629.72M |
| Average Diluted Shares Outstanding | 668.03M | 682.38M | 677.43M | 675.13M | 663.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |